摘要
Abstract
Objective To investigate the role of Ginsenosides Rg1 for non-alcoholic fatty liver disease by β-oxidation.Methods 120 SD rats were randomly divided into control group(CON),model group(HFD),Ginsenosides Rg1low,medium and high dose group (GLD ,GMD and GHD) ,sodium deoxycholate of bear treatment group (PDT ) ,20 rats in each group .After 4 and 8 weeks treatment ,the rats were sacrificed ,Pathology of hepatic tissue was tested by HE staining ,and liver function ,lipid levels ,hepatic ac-yl-CoA synthetase (CoASH1) ,carnitine acyl transferase I(CATI) and acetyl coenzyme A oxidase 1 (ACOX1) mRNA and protein expression were tested .Results After 4 weeks of treatment ,the liver function tested by HE staining only improved in GHD group . After 8 weeks ,there′s a little fat particles aggregation in PDT and GLD groups ,but no infiltration of fat in GMD and GHD groups . After 4 weeks ,AST ,ALT and AKP ,CHOL ,TG and LDL-C levels were significantly lower in PDT ,GLD ,GMD and GHD groups compared with HFD group (P<0 .05) ,which were significant declined 8 weeks later .After 4 weeks ,HDL-C level in four groups was significantly increased ,then reached the normal level 8 weeks later .After 4 weeks ,CoASH1 ,CATI and ACOX1 expressions in hepatic tissue of four groups were significantly increased ,which improved more obviously after eight weeks .Conclusion Ginsen-oside Rg1 can improves nonalcoholic fatty liver phenotype by regulation of β-oxidation .关键词
人参皂苷Rg1/非酒精性脂肪肝病/脂酰CoA合成酶/脂酰肉毒碱转移酶I/酰基辅酶A氧化酶1Key words
Ginsenosides Rg1/non-alcoholic fatty liver disease/acyl-CoA synthetase/carnitine acyl transferase I/acetyl coen-zyme A oxidase 1分类
医药卫生
